Table 1.

Detailed inclusion and exclusion criteria regarding the type of study, age, intervention and outcomes

Criteria	Inclusion			Exclusion
Type of study	SR &MA	RCT	OS	editorials, opinion papers, case reports, case series, narrative reviews, letters, qualitative studies and observational studies which do not provide information of interest regarding adverse events
Age of participants	mean or median age ≥ 65 years, or subgroup analysis ≥ 65 years	≥ 80% of participants ≥ 65 years or a subgroup analysis ≥ 65 years
Type of intervention	efficacy and/or safety of PAI as monotherapy or in combination with any other drug for the treatment or prevention of cerebral infarction, transient ischaemic attacks, peripheral artery occlusive disease and coronary disease or one of these indications versus placebo, no treatment, other drugs or a non-pharmacological intervention			focus on acute conditions (like exclusively acute treatment of myocardial infarction during the first hours)
Clinically relevant outcomes	quality of life, mortality, life expectancy, hospitalization, cognitive impairment or cognitive status, functional impairment or functional status, cardiovascular event including stroke, renal failure, composite end points including any of the above (extraction of individual outcomes will be done if reported by original studies), adverse drug event, bleeding			surrogate endpoints (like laboratory measurements or blood pressure)

MA meta-analysis, OS observational study, RCT randomised controlled trial, SR systematic review